Affimed N.V.:
Proprietary ROCK® platform enabling generation of multi-specific antibodies is basis for its collaboration with Genentech ($96M upfront / $5B potential) to develop NK-cell engager-based therapeutics. Pipeline includes NK cell engager AFM13 (CD30/CD16A) to enter Ph 2 registration study in CD30-positive PTCL and an investigator-sponsored study by MDACC of AFM13 combined with allogeneic NK cells in relapsed/refractory CD30-positive lymphoma. IND cleared for AFM24, the company’s innate cell engager that targets EGFR-expressing solid tumors.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe, USA
Clinical Stage
Phase l or ll
Disease Space
Hematology, Immuno-Oncology, Oncology
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
Antibodies, Platform Technology
Website:
Profiles:
Address:
Im Neuenheimer Feld 582
Heidelberg, Baden-Wurttemberg 69120
Germany
Heidelberg, Baden-Wurttemberg 69120
Germany
Presentation:
Company Participants at Solebury Trout Corporate Access 1x1 Calls - Week of April 13
- Adi Hoess, Ph.D., Chief Executive Officer
- Gregory Gin, Head of Investor Relations
More info:
My account:
Upcoming Company Event Participation
Solebury Trout Virtual Management Access Event
January 6 –
January 15, 2021
Lead Programs
AFM13
Disease Target CD30 Immune Cell Target CD16A
| Indication | Phase |
|---|---|
| Hodgkin lymphoma + PD-1 | 1 |
| Hodgkin lymphoma | 2 |
| Hodgkin lymphoma + adoptive NK cells | Pre-clinical |
| CD30-positive lymphoma | 2 |
AFM24
Disease Target EGFRwt Immune Cell Target CD16A
| Indication | Phase |
|---|---|
| Solid tumors | Pre-clinical |
Top 10 Holders of Affimed N.V.
| Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
|---|---|---|---|---|---|
| NEA Management Co. | 9.81 | 6,126,488 | 20.22 | 13F | 6/30/20 |
| Millennium Management LLC | 8.05 | 5,026,125 | 16.59 | 13F | 6/30/20 |
| 683 Capital Management LLC | 5.85 | 3,650,000 | 12.05 | 13F | 6/30/20 |
| Point72 Asset Management LP (Old) | 5.54 | 3,461,093 | 11.42 | 13F | 6/30/20 |
| BlackRock Fund Advisors | 5.22 | 3,260,744 | 10.76 | 13F | 6/30/20 |
| FundLogic SASU | 4.18 | 2,610,292 | 8.61 | 13F | 6/30/20 |
| Acadian Asset Management LLC | 4.18 | 2,607,112 | 8.60 | 13F | 6/30/20 |
| Bain Capital Public Equity Management II LLC | 3.59 | 2,241,201 | 7.40 | 13F | 6/30/20 |
| Citadel LP | 2.50 | 1,562,807 | 5.16 | 13F | 6/30/20 |
| State Street Corp. | 2.39 | 1,493,695 | 4.93 | 13F | 6/30/20 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.